Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $9 to $6.
Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $9 to $6.